We have created a new method based on the ROPRO (oncology prognostic score). Our method analyses the longitudinal response of patient cohorts to medications. We conducted a retrospective analysis, where we recreated clinical trials from a large real-world dataset and from real in-house clinical trials. Using this new method we detected the treatment benefit earlier than with established methodology. This case study is showing great promise as a clinical development decision support tool.